‹ All Posts
Saurabh Tyagi--Clovek,Advisory

7th Apr 2025 · SEBI-Registered Analyst

SUNPHARMA
launches medication for Erosive Esophagitis

SUNPHARMA
has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.

#WatchOutFor#StockInNews#FundamentalViews#EquityResearch#MacroViews
273 likes·79 comments